痰热清联合更昔洛韦对小儿呼吸道合胞病毒性肺炎的治疗

Treatment of pediatric respiratory syncytial virus pneumonia with tanreqing and ganciclovir

[目的]研究痰热清联合更昔洛韦治疗小儿呼吸道合胞病毒性肺炎的临床疗效。[方法]将收治的116例呼吸道合胞病毒性肺炎患儿随机分为2组,每组各58例。对照组,利巴韦林治疗;治疗组,联合痰热清与更昔洛韦治疗。评价临床疗效,比较不良反应。[结果]治疗组,31例治愈,23例有效,4例无效,总有效率为93.1%(54/58);对照组,19例治愈,28例有效,11例无效,总有效率为81.1%(47/58)。经数据比较,有统计学意义(P<0.05)。不良反应:治疗组发生率为6.9%(4/58),对照组为5.1%(3/58),组间没有明显差异(P>0.05)。[结论]联合痰热清与更昔洛韦治疗小儿呼吸道合胞病毒性肺炎,疗效显著,且安全性高。

[Objective]To study the clinical efficacy of tanreqing and gancielovir in the treatment of children with respiratory syncytial virus pneumonia. [Methods]116 children with respiratory syneytial virus pneumonia were randomly divided into 2 groups, 58 eases in each group. Control group, ribavirin treatment; Treatment group, combined with pyelonephrine and ganeielovir treatment. Evaluate clinical efficacy and compare adverse reactions.[Results]In the treatment group, 31 eases were cured, 23 eases were effective, 4 eases were ineffective, and the total effective rate was 93.1% （54/58）; In the control group, 19 eases were cured, 28 eases were effective, and 11 eases were ineffective. The total effective rate was 81.1% （47/58）. By comparison of the data, there was statistical significance （ P 〈 0.05）. Adverse reactions： The treatment group was 6.9% （4/58）; The control group was 5.1% （3/58）, and there was no significant difference between the groups （ P 〉 0.05）. [Conclusion]Combination of Tanreqing and Gancielovir in the treatment of children with respiratory syneylial virus pneumonia, The effect is significant and the safety is high.